Learning Objectives

  • Demonstrate an increase in your knowledge of clinical medicine.
  • Evaluate the appropriateness of clinical information as it applies to the care of your patients.
  • Demonstrate an improvement in your ability to make decisions that provide safe and effective medical care.
  • Recognize areas of personal strength and areas for growth in clinical knowledge.

Intended Audience

Physician assistants and physician assistant students who are seeking to maintain and augment their knowledge and/or who are preparing for their initial board certification or recertification.

AAPA Self-Assessment CME Credit

AAPA Category 1 Self-Assessment CMEThis activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 225 AAPA Category 1 Self-Assessment CME credits. PAs should only claim credit commensurate with the extent of their participation. Approval is valid from 6/1/2023 to 6/1/2024. AAPA reference number: 209296.

For NCCPA certification maintenance ONLY: NCCPA will now apply an additional 50 percent weighting when these self-assessment credits are logged for NCCPA certification maintenance purposes. PAs should log up to a maximum of 225 AAPA Category 1 Self-Assessment CME credits, as the additional weighting will be automatically applied by NCCPA.

You will receive one credit for every ten questions you answer correctly.

CME Disclosure

All persons who may impact the content of a CME activity, including faculty and planners, are required to fully disclose current and recent financial relationships with commercial interests. A conflict of interest may be considered to exist if such a person has financial relationships with the grantor or any non-eligible entities (commercial interests) that may have a direct impact on the content of the program. Financial relationship is defined as being a shareholder, consultant, grant recipient, research participant, employee, and/or recipient of other financial or material support. Recent is defined as within the past 24 months.

MMS Disclosure Policy

The Massachusetts Medical Society (MMS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) and must ensure independence, balance, and scientific rigor in its accredited continuing education activities. All individuals in control of the content for an MMS accredited continuing education activity must disclose all financial relationships with ineligible companies.

Individual Disclosures

Below are all relevant financial relationships reported by NEJM Knowledge+ contributors during the past 3 years. Vaneeta Bamba, MD
2021Novo Nordisk, Growth Advisory Board for Genetic Short Stature, discontinued Nov 2020
2022Nothing disclosed
2023Nothing disclosed
  Ethan Brown, MD
2021Rune Labs, consultant, discontinued Apr 2019
2022Rune Labs, consultant
2023Nothing disclosed
  Steven Chen, MD
2022Pfizer, advisory board member, discontinued May 2021 Novartis, advisory board member, discontinued Dec 2021
  Ezra M. Cohen, MD
2021Cornerstone Research Group, consultant
2022Nothing disclosed
2023Presidio, scientific board member
  Nathan Connell, MD
2021Nothing disclosed
2022Takeda Pharmaceutical, consultant
2023Takeda Pharmaceutical, consultant Octapharma, honoraria Genentech, advisory board member Doximity, equity
  Areeg H. El-Gharbawy, MD
2021Ultragenyx, principal investigator for a clinical trial Ultragenyx, advisory board member Amicus, advisory board member
  Rajesh T. Gandhi, MD
2021Merck, scientific advisory board
2022Nothing disclosed
2023Nothing disclosed
  Glenn J. Hanna, MD
2022Actuate Therapeutics, grant/funding Bicara, consultant/advisory board Bicara, grant/funding Boxer Capital, consultant Bristol Myers Squibb, grant/funding Bristol Myers Squibb, consultant Coherus, consultant Elevar, consultant/advisory board Exicure, grant/funding, discontinued Jan 2022 Exicure, consultant/advisory board Gateway for Cancer Research, grant/funding Genentech, grant/funding General Catalyst, consultant GlaxoSmithKline, grant/funding ImmunityBio, grant/funding Kartos Therapeutics, grant/funding Kite Pharma, grant/funding, discontinued Jun 2022 KSQ Therapeutics, consultant KSQ Therapeutics, grant/funding Kura Oncology, consultant/advisory board Kura Oncology, grant/funding Merck, consultant/advisory board Naveris, consultant/advisory board Prelude, consultant/advisory board Rain Therapeutics, consultant, discontinued Nov 2021 Regeneron, consultant/advisory board Regeneron, grant/funding Remix Therapeutics, consultant/advisory board Repertoire, grant/funding Sanofi Genzyme, advisory board, discontinued Nov 2021 Sanofi Genzyme, grant/funding Secura Bio, grant/funding V Foundation, grant/funding, discontinued Jun 2022
  Jonathan S. Hausmann, MD
2021Pfizer, consultant, discontinued Dec 2020 Biogen, consultant, discontinued Dec 2020 Novartis, consultant
2022Pfizer, consultant, discontinued Dec 2020 Biogen, consultant, discontinued Dec 2020 Novartis, consultant
2023Fresenius Kabi, consultant Novartis, consultant
  Brian C. Healy, MD
2021Analysis Group, grant support Celgene (Bristol Myers Squibb), grant support Verily, grant support Novartis, grant support Merck Serono, grant support Genzyme, grant support
2022Analysis Group, research support to institution, discontinued Nov 2020 Celgene (Bristol Myers Squibb), research support to institution, discontinued Nov 2020 Novartis, research support
2023Novartis, research support
  Koyal Jain, MD, MPH
2022PI for Kaneka study and Visterra study
  Mihir M. Kamdar, MD
2021Amorsa Therapeutics, scientific advisory board, stockholder Medtronic, consultant, fees Fern Health, consultant, fees
2022Nothing disclosed
2023Elevate, cofounder and chief medical officer Fern Health, medical advisor
  Ruslan Korets, MD
2021Boston Scientific, consultant
2022Boston Scientific, consultant
2023Boston Scientific, consultant
  Lekha M. Rao, MD
2023Epigenyx Therapeutics, consultant UCB, principal investigator for a clinical trial Eisai, principal investigator for a clinical trial
  Leigh C. Reardon, MD
2021Janssen, speaker CareDx, participant in advisory board discussion, discontinued Dec 2020
2022Janssen, advisory committee
2023Janssen, consultant
  Eric Roeland, MD
2023Napo Pharmaceuticals, scientific advisory board Actimed Therapeutics, scientific advisory board Meter Health, scientific advisory board Veloxis Pharmaceuticals, consultant Aileron Therapeutics, consultant BYOMass, consultant Takeda, advisory board Enzychem Lifesciences Pharmaceutical Company, data safety monitoring board
  Deborah R. Stein, MD
2021Nothing disclosed
2022Nothing disclosed
2023Horizon, consultant Alexion, consultant
  Joji Suzuki, MD
2023Indivior, research support, discontinued Aug 2023
  Taher S. Valika, MD
2021Save My Scope Inc, chief medical officer
  Ruth Ann Vleugels, MD, MPH, MBA
2021Pfizer, principal investigator for a clinical trial
  Raymond Y. Wang, MD
2021Biomarin Pharmaceutical, speaking engagement, discontinued Jul 2019 Biomarin Pharmaceutical, advisory committee, discontinued Sep 2019 RegenxBio, advisory committee, discontinued May 2020 Takeda Pharmaceutical, advisory committee, discontinued Aug 2020 Ultragenyx Pharmaceutical, webinar, discontinued Nov 2020 Inventiva Pharmaceutical, advisory committee, discontinued Dec 2020 Neurogene, advisory committee, discontinued Nov 2020 Denali Therapeutics, drug monitoring committee
2022Biomarin, ad hoc advisory board, discontinued Oct 2021 Orphazyme, ad hoc FDA advisory meeting, discontinued Oct 2021 Sio Gene Therapies, consultant, discontinued Nov 2021 Sio Gene Therapies, ad hoc advisory board, discontinued Aug 2021 Inventiva Pharmaceutical, ad hoc advisory board, discontinued Jul 2021 Takeda Pharmaceutical, ad hoc advisory board, discontinued Mar 2021 Ultragenyx, speaker, discontinued Nov 2020 Neurogene, ad hoc advisory board, discontinued Oct 2020 Regenxbio, ad hoc advisory board, discontinued Apr 2020
2023RegenxBio, consultant Takeda Pharmaceutical, advisory committee, discontinued 2022 Denali, drug safety monitoring board
  Sharmeel K. Wasan, MD
2021Pfizer, grant support
2022Nothing disclosed
2023Nothing disclosed
  All relevant financial relationships have been mitigated prior to the beginning of this activity in accordance with ACCME and MMS policies. All other individuals in control of the content have reported no relevant financial relationships with ineligible companies for this activity. The complete list of contributors can be found here.

Disclosure of Commercial Support

No commercial support was received for this activity.

Medium or Combination of Media Used

This is an adaptive self-assessment tool designed to adjust to the learner’s strengths and areas for growth, and can be accessed from a desktop, laptop, tablet, or smartphone. Learners choose the subspecialty area and are presented with a sequence of questions. After each question is answered, the user is provided with the key learning point, detailed feedback that discusses the correct answer as well as each of the wrong answers, and citations to relevant articles.

Estimated Time to Complete the Educational Activity

One hour for every 10 questions answered correctly.

Bibliography

Each clinical vignette includes citations and references.

Hardware/Software Requirements

Browsers

In general, we support the two latest versions of major browsers:

  • Edge (Recommended for best performance)
  • Chrome (Recommended for best performance)
  • Firefox
  • Safari

Systems Minimum Requirements

  • Screen Size: 4.5″+ (mobile)
  • Some content types might not work on small screens
  • Win10+ with 4GB+ RAM (8GB+ recommended)
  • macOS 11+ with 4GB+ RAM (6GB+ recommended
  • Android 10+ with 2GB+ RAM
  • iOS 12+ with 2GB+ RAM (Devices from 2019+ recommended)
  • Internet bandwidth: 1Mbit/s+ bandwidth (10MBit/s recommended, depends on content type)

Contact Information

For all questions and comments, please contact NEJM Knowledge+ by email at knowledgeplussupport@nejm.org or call toll-free +1-855-318-9303 (within the USA and Canada) or +1-781-434-7998.

Policy on Privacy and Confidentiality

Read our Privacy Policy.

Copyright

Copyright information can be found in the NEJM Group Terms of Use.